On 28 February 2020, orphan designation EU/3/20/2247 was granted by the European Commission to IQVIA RDS Ireland Limited, Ireland, for 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide monohydrate (also known as CPI-0610) for the treatment of myelofibrosis.
The sponsorship was transferred to AdRes EU B.V Netherlands, in June 2020.
|Disease / condition||
Treatment of myelofibrosis
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.